Evident has completed the acquisition of CrestOptics SpA, a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy.
The acquisition broadens Evident's life science imaging portfolio and deepens its capability in high-speed, high-content 3D imaging for research, pharma, and biotech applications.
Founded in 2011, CrestOptics designs and manufactures confocal spinning disk and structured illumination microscopy (SIM) modules that integrate with microscope platforms from leading manufacturers worldwide. Its portfolio includes the X-Light family of spinning disk confocal systems, featuring precise optical sectioning and uniform illumination across a class-leading field of view; the compact CICERO widefield and spinning disk solution, which brings highly capable entry-level confocal within reach of any laboratory; and DeepSIM, a Lattice SIM super-resolution module that delivers sub-diffraction imaging with the accessibility of a widefield system. Used in laboratories around the world, CrestOptics products are built to be universally accessible tools that advance discovery without barriers.
"Researchers are asking harder questions of increasingly complex biological models, and that demands faster, gentler, higher-resolution imaging," said Wes Pringle, Evident CEO. "Our customers push the limits of science, and our role is to advance the optical technologies that make new discoveries faster and easier than ever. Evident and CrestOptics operate under a shared vision. After partnering with them, it was clear that their mission, their engineering capability, and most importantly their people, complement our own and together we can deliver more complete solutions to the scientists who depend on us."
Evident and CrestOptics have collaborated as partners for several years, with CrestOptics’ spinning disk technology already integrated into Evident microscope configurations. The acquisition formalises and expands that relationship.
"Joining Evident is a natural next step for CrestOptics," said Renato Giacobbo Scavo, Chief Executive Officer, CrestOptics. "We share a commitment to advancing what microscopy can reveal. With Evident's global reach, manufacturing strength, and applications expertise, we can accelerate our innovation roadmap and bring our technologies to many more laboratories worldwide. We are grateful to our previous investors, Apposite Capital and Primo Capital, as well as our Chairman, David Martyr, and the board of directors, for their support throughout this journey."
CrestOptics will continue to operate from its Rome headquarters and R&D and manufacturing facility and maintain its existing partner and distribution relationships, continuing to be a technology provider for the entire microscopy industry.